UCB, Teva, Novartis, Pfizer and TransCelerate Biopharma win industry recognition at the eyeforpharma Philadelphia Awards 2016

eyeforpharma 2 - 3 May 2016, Philadelphia, USA.
The 2016 eyeforpharma Philadelphia Awards saw 22 finalists, with representation from every top 20 pharma, showcase the breadth of innovation within the industry. Submissions displayed cutting-edge application of new strategies for old problems.

Teva won the Most Valuable HCP or Healthcare Initiative with their foray into Artificial Intelligence. Teva presented "ASK Claire", an Intelligent Virtual Health Assistant that engages Multiple sclerosis (MS) patients on the web and in an app.

UCB picked up the Most Valuable Patient Initiative or Service Award with their Report Cards submission. The team presented an intriguing approach to create new incentives for decision makers to prioritise innovative therapies for Epilepsy Patients, by creating transparency into current care outcomes.

Individual leaders were also recognized for their refusal to accept the status quo, showing the way for the industry to progress. Chrisi Shaw, the, U.S. Country Head and President of Novartis picked up the Lifetime Achievement Award for her leadership on gender equality and contributions to patient-centricity throughout the pharma lifecycle.

Pfizer's Dennis Freire was awarded for his contributions towards patient-centric clinical trials with the Customer Innovator Award. Through a collaboration with ICON Firecrest collaboration, Freire oversaw a radical re-think of the onerous procedures facing patient registrants for clinical trials.

The groundbreaking consortium of top 20 pharma TransCelerate was also recognized with the Most Valuable Pharma Collaboration award for the work they've achieved in unlocking innovation that benefits everyone in pharma. Through shared research partnerships and close regulatory coordination, they are redefining the boundaries of what is possible in cross-industry collaboration on issues of shared commercial, and patient-centric interest.

The awards reflect eyeforpharma's mission to evangelize the need for pharma to change its focus from selling products, to seeing the powerful opportunity that pharma has to impact and improve the lives of patients. The winning projects were selected from hundreds of initiatives submitted from teams across the global, and determined by a judging panel of senior industry experts, and patient advocates.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...